Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, designs and develops electrochemical cells in Australia.
Flawless balance sheet and fair value.
Share Price & News
How has Universal Biosensors's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: UBI's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: UBI underperformed the Australian Medical Equipment industry which returned -1.3% over the past year.
Return vs Market: UBI underperformed the Australian Market which returned -22.9% over the past year.
Price Volatility Vs. Market
How volatile is Universal Biosensors's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDo Directors Own Universal Biosensors, Inc. (ASX:UBI) Shares?
4 months ago | Simply Wall StSome Universal Biosensors (ASX:UBI) Shareholders Are Down 37%
1 year ago | Simply Wall StWhat Should Investors Know About Universal Biosensors Inc's (ASX:UBI) Capital Returns?
Is Universal Biosensors undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: UBI (A$0.15) is trading below our estimate of fair value (A$18.72)
Significantly Below Fair Value: UBI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: UBI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: UBI is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UBI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UBI is good value based on its PB Ratio (0.6x) compared to the AU Medical Equipment industry average (3.2x).
How is Universal Biosensors forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Universal Biosensors has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Universal Biosensors is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Universal Biosensors competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Universal Biosensors performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UBI is currently unprofitable.
Growing Profit Margin: UBI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UBI is unprofitable, but has reduced losses over the past 5 years at a rate of 53.3% per year.
Accelerating Growth: Unable to compare UBI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UBI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).
Return on Equity
High ROE: UBI has a negative Return on Equity (-10.68%), as it is currently unprofitable.
How is Universal Biosensors's financial position?
Financial Position Analysis
Short Term Liabilities: UBI's short term assets (A$37.1M) exceed its short term liabilities (A$10.2M).
Long Term Liabilities: UBI's short term assets (A$37.1M) exceed its long term liabilities (A$7.1M).
Debt to Equity History and Analysis
Debt Level: UBI is debt free.
Reducing Debt: UBI has no debt compared to 5 years ago when its debt to equity ratio was 91.4%.
Inventory Level: UBI has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if UBI's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UBI has been profitable on average in the past, therefore cash runway is not a concern.
Forecast Cash Runway: UBI has been profitable on average in the past, therefore cash runway is not a concern.
What is Universal Biosensors's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UBI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate UBI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UBI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UBI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UBI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Salesh Balak (50yo)
Mr. Salesh Balak, BA, CA, has been the Chief Financial Officer of Universal Biosensors Inc. since November 27, 2006 and has been its Company Secretary since December 20, 2018 also its Interim Principal Exe ...
CEO Compensation Analysis
Compensation vs Market: Salesh's total compensation ($USD241.40K) is about average for companies of similar size in the Australian market ($USD245.34K).
Compensation vs Earnings: Salesh's compensation has been consistent with company performance over the past year.
|CFO & Company Secretary||0.67yr||AU$393.57k||0.13% A$34.0k|
|Director of Operations & Manufacturing Engineering||1.67yrs||no data||no data|
|Chief Research Scientist||17.92yrs||AU$112.95k||no data|
Experienced Management: UBI's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
|Non-Executive Chairman||2.58yrs||AU$177.92k||0.12% A$33.0k|
|Independent Non-Executive Director||4yrs||AU$57.60k||0.32% A$85.0k|
|Independent Non-Executive Director||5yrs||AU$73.90k||0.056% A$15.0k|
|Independent Non-Executive Director||10.17yrs||AU$62.60k||0.011% A$3.0k|
Experienced Board: UBI's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Universal Biosensors, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Universal Biosensors, Inc.
- Ticker: UBI
- Exchange: ASX
- Founded: 2001
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$26.636m
- Shares outstanding: 177.57m
- Website: https://www.universalbiosensors.com
Number of Employees
- Universal Biosensors, Inc.
- 1 Corporate Avenue
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UBI||ASX (Australian Securities Exchange)||Yes||NPV (CDI)||AU||AUD||Dec 2006|
|UBI||CHIA (Chi-X Australia)||Yes||NPV (CDI)||AU||AUD||Dec 2006|
Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, designs and develops electrochemical cells in Australia. The company focuses on the research, development, and manufacture of medical or testing devices. It uses electrochemical cell technology platform to develop point of use devices for various industries, including healthcare, food and drink, and agriculture. The company offers prothrombin time international normalized ratio coagulation test strips; and coagulation testing and calibration services, as well as distributes Siemens’ Xprecia Stride Coagulation Analyzer. It also owns, operates, and manages a hemostasis laboratory. The company was founded in 2001 and is based in Rowville, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 10:39|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.